Home » Stocks » PCSA

Processa Pharmaceuticals, Inc. (PCSA)

Stock Price: $7.13 USD -0.04 (-0.50%)
Updated December 2, 10:19 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 75.37M
Revenue (ttm) n/a
Net Income (ttm) -5.45M
Shares Out 5.59M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $7.13
Previous Close $7.17
Change ($) -0.04
Change (%) -0.50%
Day's Open 7.17
Day's Range 6.79 - 7.17
Day's Volume 5,885
52-Week Range 3.95 - 7.17

More Stats

Market Cap 75.37M
Enterprise Value 76.84M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 5.59M
Float n/a
EPS (basic) -1.05
EPS (diluted) -1.08
FCF / Share -0.43
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8,067
Short Ratio 0.26
Short % of Float n/a
Beta -0.75
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 11.14
Revenue n/a
Operating Income -5.66M
Net Income -5.45M
Free Cash Flow -2.38M
Net Cash -1.47M
Net Cash / Share -0.14
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -22.39%
ROE -76.82%
ROIC 568,678.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $7.13
Target: 12.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth----5.77%-65.68%62.63%-
Gross Profit-----
Operating Income-3.94-4.52-1.80-1.92-2.69-2.55-2.96-2.27
Net Income-3.36-3.77-1.86-1.92-3.35-4.53-3.07-2.44
Shares Outstanding5.535.334.664.
Earnings Per Share-0.70-0.71-0.42-0.49-15.19-33.32-29.89-73.50
Operating Cash Flow-2.75-3.71-1.65-2.16-0.87-2.69-2.54-1.89
Capital Expenditures--0.02-0.02-0.020.03-0.01-0.03-0.33
Free Cash Flow-2.75-3.73-1.68-2.18-0.84-2.70-2.57-2.23
Cash & Equivalents0.691.742.852.090.00-0.191.02
Total Debt1.030.232.45-1.370.570.781.13
Net Cash / Debt-0.341.510.402.09-1.36-0.57-0.59-0.11
Book Value8.019.700.372.27-1.981.211.672.56
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Processa Pharmaceuticals, Inc.
Employees 13

Stock Information

Ticker Symbol PCSA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PCSA


Processa Pharmaceuticals, a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of post-operative ileus; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It also has license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was founded in 2015 and is based in Hanover, Maryland.